Baxter buyback seeks $2 billion
DEERFIELD -- Baxter International Inc., maker of hemophilia drugs and the recalled blood thinner heparin, may buy back as much as $2 billion in additional shares after completing an existing repurchase program. The company has less than $700 million remaining from a $2 billion repurchase authorized a year ago, Baxter said Tuesday in a statement.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.